 |
Dedicated to precision medical services and product development |
|
|
| |
| An EGFR triple mutation and Osimertinib-resistant NSCLC PDX model |
LIDE Biotech have established 86 lung cancer PDX models out of total >1100 cancer PDX models. Here we report PDX models with TKI drug-associated EGFR mutations (L858R, T790M, Exon19del, C797S), particularly a clinically nature-occurred AZD9291-resistant EGFR triple mutant (Ex19del, T790M, C797S) PDX model, LD1-0025-200717 which is the unique PDX model for developing the new drug candidates that overcome 奥希替尼(Osimertinib)(AZD9291) drug resistant at clinic
|
|
| |
| |
| Efficacy study in LD1-0025-200717 |
|
| |
|
| |
| Efficacy study in LD1-0025-200717 |
|
| |
|
A. EGFR triple mutant (Ex19del, T790M, C797S) model LD1-0025-200717 was resistant to Erlotinib and AZD9291, and also resistant to Erlotinib+ AZD9291. |
|
B. LD1-0025-200717 was resistant to higher dose of AZD9291.
|
|
| |
|
|
|
EGFR triple mutant (Ex19del, T790M, C797S) model LD1-0025-200717 was resistant to Cetuximab and EAI045, and also resistant to Cetuximab + EAI045. And this model is sensitive to Brigatinib, Brigatinib + Cetuximab Combo can reverse drug resistance of the EGFR triple Mutant PDX model. |
|
| |
| An Assembly of Lung PDX Models with EGFR Mutations |
|
| |
Model ID |
EGFR (IHC) |
EGFR mutant |
c-Met mutation |
c-Met expression (CPM) |
c-Met (IHC) |
RET |
ALK |
ROS |
BRAF |
KRAS |
LD1-0006-217645 |
|
19del T790M |
|
|
|
wt |
wt |
wt |
wt |
|
LD1-0006-217655 |
|
19del (746-750) |
|
|
|
wt |
wt |
wt |
wt |
|
LD1-0006-217683 |
|
19del (745-749) |
|
|
|
wt |
wt |
wt |
wt |
|
LD1-0025-200713 |
|
L858R |
|
|
|
wt |
wt |
wt |
wt |
|
LD1-0025-200717 |
++ |
19del T790M C797S |
wt |
|
+ |
wt |
wt |
wt |
wt |
|
LD1-0025-200730 |
|
L858R |
|
|
|
wt |
wt |
wt |
G469R |
|
LD1-0025-200739 |
|
19del (747-751) |
|
|
|
wt |
wt |
wt |
wt |
|
LD1-0025-360961 |
|
19del (746-750) |
|
|
|
wt |
wt |
wt |
wt |
|
LD1-0025-200630 |
++ |
L858R |
wt |
68.37 |
- |
wt |
wt |
wt |
wt |
wt |
LD1-0025-200662 |
+++ |
19del (748-753) |
wt |
3333.6 |
+++ |
wt |
wt |
wt |
wt |
wt |
|
| |
|
|
|
| |
|
TEL:400-821-0176
E-mail:CRO@lidebiotech.com
Add:3F, Building 77-78, 887 Zuchongzhi Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, China, 201203.
Get more clinical information，click on the URL below.
http://www.lidebiotech.com/ |
 |
| |
|
|
| |
| About LIDE |
|
| |
Shanghai LIDE Biotechnology Co., Ltd. ("Shanghai LIDE"), is committed to translational medicine and precision medical research of cancer, provide drug treatment guides to physicians, and proposing personalized treatment plans. The company owns AAALAC accredited SPF level animal centers and world-class equipment. Shanghai LIDE has two wholly-owned subsidiaries, "Xi'an LIDE Biotechnology Co., Ltd." and "Shanghai LIWEN Diagnostics Co., Ltd." (hereinafter referred to as "Shanghai LIWEN") both with qualification of clinical testing laboratory.
|
| |
|